Africa Preeclampsia Laboratory Testing Market - Latest Scenario and Future Aspect Analysis 2022-2027

Preeclampsia Laboratory Testing Market to Witness Substantial Growth Driven by Urgent Demand for Improved Diagnostics

The global preeclampsia laboratory testing market is poised to experience significant growth in the coming years, driven by the pressing need for reliable diagnostic solutions for preeclampsia, a multisystem pregnancy complication characterized by high blood pressure and organ dysfunction. The current symptoms associated with preeclampsia often overlap with those of normal pregnancies, making diagnosis challenging. Consequently, the development of innovative and accurate screening methods for preeclampsia is of utmost importance.

Access Full Report: https://www.fairfieldmarketresearch.com/report/preeclampsia-laboratory-testing-market

According to Fairfield Market Research, the global preeclampsia laboratory testing market is projected to reach a value of US$17,386.1 million by 2027, with a robust compound annual growth rate (CAGR) of 4.6% during the forecast period (2022-2027). The increasing burden of preeclampsia, primarily attributed to lifestyle disorders, coupled with advancements in medical technologies worldwide, is expected to drive the demand for preeclampsia laboratory testing. The market is estimated to witness revenues of US$13,863.3 million in 2022, with a volume of approximately 122,998 (in thousands), representing the number of women undergoing diagnostic tests by the end of 2027.

Developing countries, in particular, are focusing on innovative diagnostic solutions to address the rising incidence of preeclampsia. The World Health Organization (WHO) reports that developing countries have a seven-fold higher incidence of preeclampsia compared to developed nations. To bridge this diagnostic gap, companies are collaborating with research institutes and universities to develop cost-effective screening kits. The development of early diagnostic tests holds the potential to significantly reduce maternal and infant mortality rates associated with preeclampsia.

Governments and academic institutions are also joining forces to improve diagnostics and treatment for preeclampsia. The University of Strathclyde, in collaboration with King's College London, has received an Artificial Intelligence Health and Care award and funding from the UK Government for their research in this area. Additionally, the emergence of innovative alternatives like hand-held screening devices is expected to further boost the adoption of diagnostic tests in the preeclampsia laboratory testing market.

One of the key drivers for market growth is the promise of novel biomarkers that can enhance diagnostic accuracy and precision. Multiple biomarkers are currently under development to address the unmet need for reliable diagnostic assessments of preeclampsia and its severity. Notably, circulating cell-free RNA (cfRNA) shows promise as a non-invasive diagnostic tool, although further studies are required to map cfRNA signatures in disease pathogenesis and create disease-specific reference databases. The blood tests segment is anticipated to contribute approximately 41% to the global preeclampsia laboratory testing market in 2021.

Currently, developed countries such as North America and Europe hold the largest share in the preeclampsia laboratory testing market due to their technologically advanced diagnostic laboratories and awareness about the importance of early preeclampsia screening. Europe is expected to witness the highest CAGR of 6.2% during the forecast period, owing to ongoing investigations into diagnostic tests for preeclampsia.

Asia Pacific, with its large population of women of reproductive age, presents significant growth potential for the preeclampsia laboratory testing market. Low- and middle-income countries in this region are projected to experience the highest growth rates, driven by increasing incidences of preeclampsia and the urgent need for its diagnosis. Notably, a study published in the Pregnancy Hypertension journal in October 2019 revealed a rise in the prevalence of preeclampsia in China from 5.79% in 2005 to 9.50% in 2019. However, lack of awareness and cost-effective screening tests pose challenges to market growth in these regions.

The decline in fertility rates worldwide and the introduction of intervening procedures aimed at reducing the risk of developing preeclampsia may impede the market growth in the near future. However, market players are prioritizing research and development activities and engaging in collaborative efforts to strengthen their positioning. Key players in the global preeclampsia laboratory testing market include PerkinElmer Inc., Siemens Healthineers AG, Thermo Fisher Scientific Inc., F. Roche Hofmann Progenity, Inc., GestVision, Inc., Metabolomic Diagnostics Ltd., DiabetOmics Inc., DRG INSTRUMENTS GmbH, Lifeassay Diagnostics (Pty) Ltd, and Quidel Corporation, among others.

As the demand for accurate and cost-effective diagnostic tests for preeclampsia continues to rise, market players are poised to make significant advancements in this field, providing hope for improved outcomes for mothers and infants worldwide.